{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:30:45Z","timestamp":1791855045089,"version":"4.3.4"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Type 2 diabetes mellitus (T2DM) and major depressive disorder (MDD) frequently co-occur, highlighting the need to understand the metabolic effects of antidepressants. This systematic review evaluated the impact of citalopram and escitalopram on glucose and lipid metabolism, focusing on glycemic control.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive search of PubMed, Embase, Web of Science, PsycINFO, the Cochrane Library and Google Scholar was conducted. Primary outcomes included changes in glycosylated hemoglobin (HbA1c) and fasting blood glucose (FBG). Secondary outcomes assessed lipid profiles (triglycerides, cholesterol, high-density lipoprotein, and low-density lipoprotein) and depressive symptom scales. Subgroup analyses were conducted to evaluate outcomes in patients with comorbid T2DM and MDD and those with MDD only.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirteen studies involving 502 participants met the inclusion criteria. Six randomized controlled trials, four prospective studies, one cohort trial, one single-arm trial and one three-arm trial. The findings suggest that both citalopram and escitalopram tend to reduce HbA1c and FBG levels. No significant effects on lipid profiles were observed across the included studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Citalopram and escitalopram appear to exert beneficial effects on glycemic control, as evidenced by reductions in HbA1c and FBG. Further high-quality investigations are warranted to validate these findings and guide individualized treatment strategies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic review registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024544963<\/jats:uri>, identifier CRD42024544963.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1578326","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T05:28:25Z","timestamp":1750138105000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of the selective serotonin reuptake inhibitors citalopram and escitalopram on glucolipid metabolism: a systematic review"],"prefix":"10.3389","volume":"16","author":[{"given":"Yajing","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhe","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JinQi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengfei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonglin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sugai","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories 1990\u20132017: a systematic analysis for the global burden of disease study 2017","volume":"392","year":"2018","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/S0165-0327(12)70004-6","article-title":"Epidemiology of depression and diabetes: a systematic review","author":"Roy","year":"2012","journal-title":"J Affect Disord"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5498\/wjp.v14.i10.1429","article-title":"Bidirectional relationship between diabetes mellitus and depression: Mechanisms and epidemiology","volume":"14","author":"Liu","year":"2024","journal-title":"World J Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2017.04.036","article-title":"Regulation of tight-junction integrity by insulin in an in vitro model of human blood-brain barrier","volume":"106","author":"Ito","year":"2017","journal-title":"J Pharm Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.pharmthera.2012.07.006","article-title":"Insulin in the brain: there and back again","volume":"136","author":"Banks","year":"2012","journal-title":"Pharmacol Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-02065-4","article-title":"Insulin effects on core neurotransmitter pathways involved in schizophrenia neurobiology: a meta-analysis of preclinical studies. Implications for the treatment","volume":"28","author":"De Bartolomeis","year":"2023","journal-title":"Mol Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105179","article-title":"Impact of insulin and insulin resistance on brain dopamine signalling and reward processing - An underexplored mechanism in the pathophysiology of depression","volume":"149","author":"Gruber","year":"2023","journal-title":"Neurosci Biobehav Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-021-00390-6","article-title":"The aetiology and molecular landscape of insulin resistance","volume":"22","author":"James","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30113-3","article-title":"Central nervous pathways of insulin action in the control of metabolism and food intake","volume":"8","author":"Kullmann","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12974-017-0985-4","article-title":"Antidiabetic drug glyburide modulates depressive-like behavior comorbid with insulin resistance","volume":"14","author":"Su","year":"2017","journal-title":"J Neuroinflamm"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2732","article-title":"Antioxidant treatment ameliorates experimental diabetes-induced depressive-like behaviour and reduces oxidative stress in brain and pancreas","volume":"32","author":"R\u00e9us","year":"2016","journal-title":"Diabetes Metab Res Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/PSY.0000000000000707","article-title":"The association between selective serotonin reuptake inhibitors and glycemia: A systematic review and meta-analysis of randomized controlled trials","volume":"81","author":"Tharmaraja","year":"2019","journal-title":"Psychosom Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/BF01244820","article-title":"The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer","volume":"88","author":"Hyttel","year":"1992","journal-title":"J Neural Transm Gen Sect"},{"key":"B14","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1186\/s12888-023-05382-8","article-title":"Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis","volume":"23","author":"Yin","year":"2023","journal-title":"BMC Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00606.2009","article-title":"Treatment with an SSRI antidepressant restores hippocampo-hypothalamic corticosteroid feedback and reverses insulin resistance in low-birth-weight rats","volume":"298","author":"Buhl","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-020-0688-x","article-title":"Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report","volume":"45","author":"Dunlop","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12911-019-0964-z","article-title":"Expression alteration of microRNAs in Nucleus Accumbens is associated with chronic stress and antidepressant treatment in rats","volume":"19","author":"Song","year":"2019","journal-title":"BMC Med Inform Decis Mak"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.05.013","article-title":"Functional connectivity of the hippocampus in predicting early antidepressant efficacy in patients with major depressive disorder","volume":"291","author":"Xiao","year":"2021","journal-title":"J Affect Disord"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147483","article-title":"Escitalopram targets oxidative stress, caspase-3, BDNF and meCP2 in the hippocampus and frontal cortex of a rat model of depression induced by chronic unpredictable mild stress","volume":"22","author":"Dionisie","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bbi.2015.12.020","article-title":"Mouse chronic social stress increases blood and brain kynurenine pathway activity and fear behaviour: Both effects are reversed by inhibition of indoleamine 2,3-dioxygenase","volume":"54","author":"Fuertig","year":"2016","journal-title":"Brain Behav Immun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1139\/cjpp-2013-0168","article-title":"Comparison of the effects of escitalopram and atorvastatin on diet-induced atherosclerosis in rats","volume":"92","author":"Unis","year":"2014","journal-title":"Can J Physiol Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2010.02530.x","article-title":"Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations","volume":"66","author":"Bro\u017cek","year":"2011","journal-title":"Allergy"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clin Res Ed)"},{"key":"B24","article-title":"Treatment of depression in type 2 diabetes with Fluoxetine or Citalopram","volume":"16","author":"Khazaie","year":"2011","journal-title":"Neurosci (Riyadh Saudi Arabia)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2013.03.007","article-title":"Diabetes with comorbid depression: role of SSRI in better glycemic control","volume":"6","author":"Gehlawat","year":"2013","journal-title":"Asian J Psychiatr"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.05.009","article-title":"Treatment of depression in type 2 diabetic patients: effects on depressive symptoms, quality of life and metabolic control","volume":"101","author":"Nicolau","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.13040\/IJPSR.0975-8232.6(10).4304-09","article-title":"Comparative effect of agomelatine versus escitalopram on glycemic control and symptoms of depression in patients with type 2 diabetes mellitus and depression","volume":"6","author":"Kumar","year":"2015","journal-title":"Int J Pharm Sci Res"},{"key":"B28","article-title":"Effect of escitalopram on glycemic control in type 2 diabetes mellitus patients with depression","volume":"10","author":"Subedi","year":"2020","journal-title":"J Chitwan Med Coll"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13777","article-title":"The relationship between depression and metabolic control parameters in type 2 diabetic patients: A cross-sectional and feasibility interventional study","volume":"75","author":"Khassawneh","year":"2021","journal-title":"Int J Clin Pract"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3329\/ssmcj.v29i2.58854","article-title":"Efficacy of escitalopram (SSRI) for better glycemic control in the diabetic depressive patients","volume":"29","author":"Israt","year":"2022","journal-title":"Sir Salimullah Med Coll J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6721695","article-title":"Effect of compound lactic acid bacteria capsules on the small intestinal bacterial overgrowth in patients with depression and diabetes: A blinded randomized controlled clinical trial","volume":"2022","author":"Wei","year":"2022","journal-title":"Dis Markers"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e42585","DOI":"10.7759\/cureus.42585","article-title":"Metabolic effects of antidepressants: results of a randomized study\u2019s interim analysis","volume":"15","author":"Santi","year":"2023","journal-title":"Cureus"},{"key":"B33","article-title":"Effect of intervention on glycemic control among adult population with type 2 diabetes mellitus and comorbid depression in Central Karnataka, India","volume":"8","author":"Shubha","year":"2023","journal-title":"RGUHS Natl J Public Health"},{"key":"B34","doi-asserted-by":"publisher","first-page":"S291","DOI":"10.1192\/bjo.2024.693","article-title":"Effect of escitalopram on glycemic control and C-reactive protein in patients with depression and co morbid type 2 diabetes mellitus\u2013a study on Indian population","volume":"10","author":"Tiwary","year":"2024","journal-title":"BJPsych Open"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.14101251","article-title":"Ziprasidone augmentation of escitalopram for major depressive disorder: efficacy results from a randomized, double-blind, placebo-controlled study","volume":"172","author":"Papakostas","year":"2015","journal-title":"Am J Psychiatry"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.5455\/njppp.2018.8.0412120042018","article-title":"Comparison of efficacy and safety of escitalopram and vilazodone in major depressive disorder","volume":"8","author":"Kudyar","year":"2018","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8202","article-title":"Genetic overlap between type 2 diabetes and major depressive disorder identified by bioinformatics analysis","volume":"7","author":"Ji","year":"2016","journal-title":"Oncotarget"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1159\/000479637","article-title":"Type 2 diabetes mellitus is associated with social recognition memory deficit and altered dopaminergic neurotransmission in the amygdala","volume":"24","author":"Parashar","year":"2018","journal-title":"Ann Neurosci"},{"key":"B39","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.bbr.2016.06.060","article-title":"Dopamine D1 receptor activity is involved in the increased anxiety levels observed in STZ-induced diabetes in rats","volume":"313","author":"Rebolledo-Solleiro","year":"2016","journal-title":"Behav Brain Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2014.00846","article-title":"Leptin and insulin signaling in dopaminergic neurons: relationship between energy balance and reward system","volume":"5","author":"Khanh","year":"2014","journal-title":"Front Psychol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101234","article-title":"The brain as an insulin-sensitive metabolic organ","volume":"52","author":"Milstein","year":"2021","journal-title":"Mol Metab"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2337\/db06-0376","article-title":"Attenuation of insulin-evoked responses in brain networks controlling appetite and reward in insulin resistance: the cerebral basis for impaired control of food intake in metabolic syndrome","volume":"55","author":"Anthony","year":"2006","journal-title":"Diabetes"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.17050550","article-title":"Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: A retrospective study based on 2,087 patients","volume":"175","author":"Juki\u0107","year":"2018","journal-title":"Am J Psychiatry"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-02285-8","article-title":"Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial","volume":"28","author":"Johansen","year":"2023","journal-title":"Mol Psychiatry"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2020.01.005","article-title":"Relationship between psychosocial factors and glucose control in adults with type 2 diabetes","volume":"44","author":"Roy","year":"2020","journal-title":"Can J Diabetes"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2018.03.011","article-title":"Escitalopram alleviates stress-induced Alzheimer\u2019s disease-like tau pathologies and cognitive deficits by reducing hypothalamic-pituitary-adrenal axis reactivity and insulin\/GSK-3\u03b2 signal pathway activity","volume":"67","author":"Wu","year":"2018","journal-title":"Neurobiol Aging"},{"key":"B47","doi-asserted-by":"publisher","first-page":"22096","DOI":"10.1038\/s41598-020-79220-2","article-title":"Brain structural network alterations related to serum cortisol levels in drug-na\u00efve, first-episode major depressive disorder patients: a source-based morphometric study","volume":"10","author":"Nguyen","year":"2020","journal-title":"Sci Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S294555","article-title":"Evaluation of stress and associated biochemical changes in patients with type 2 diabetes mellitus and obesity","volume":"14","author":"Tyagi","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B49","doi-asserted-by":"publisher","first-page":"E268","DOI":"10.1152\/ajpendo.00314.2018","article-title":"Mitochondrial dysfunction in type 2 diabetes mellitus: an organ-based analysis. American journal of physiology. Mitochondrial dysfunction in type 2 diabetes mellitus: an organ-based analysis","volume":"316","author":"Pinti","year":"2019","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-0724-6","article-title":"Potential depression and antidepressant-response biomarkers in human lymphoblast cell lines from treatment-responsive and treatment-resistant subjects: roles of SSRIs and omega-3 polyunsaturated fatty acids","volume":"26","author":"Chukaew","year":"2021","journal-title":"Mol Psychiatry"},{"key":"B51","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1177\/02698811231152748","article-title":"Associations of antidepressants and antipsychotics with lipid parameters: Do CYP2C19\/CYP2D6 genes play a role? A UK population-based study","volume":"37","author":"Richards-Belle","year":"2023","journal-title":"J Psychopharmacol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"993","DOI":"10.7326\/M23-2742","article-title":"Medication-induced weight change across common antidepressant treatments: A target trial emulation study","volume":"177","author":"Petimar","year":"2024","journal-title":"Ann Intern Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104758","article-title":"Insulin resistance in depression: A large meta-analysis of metabolic parameters and variation","volume":"139","author":"Fernandes","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"B54","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.bbi.2021.05.010","article-title":"High-fat diet induces neuroinflammation and reduces the serotonergic response to escitalopram in the hippocampus of obese rats","volume":"96","author":"Hersey","year":"2021","journal-title":"Brain Behav Immun"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ynstr.2016.05.001","article-title":"Pioglitazone, a PPAR\u03b3 agonist rescues depression associated with obesity using chronic unpredictable mild stress model in experimental mice","volume":"3","author":"Kurhe","year":"2016","journal-title":"Neurobiol Stress"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2020.104674","article-title":"PPAR\u03b3-mediated microglial activation phenotype is involved in depressive-like behaviors and neuroinflammation in stressed C57BL\/6J and ob\/ob mice","volume":"117","author":"Qin","year":"2020","journal-title":"Psychoneuroendocrinology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2012.58","article-title":"Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial","volume":"37","author":"Sepanjnia","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2014.06.020","article-title":"QCM-4, a serotonergic type 3 receptor modulator attenuates depression co-morbid with obesity in mice: an approach based on behavioral and biochemical investigations","volume":"740","author":"Kurhe","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-017-4558-0","article-title":"Novel 5-HT(3) receptor antagonist QCM-4 attenuates depressive-like phenotype associated with obesity in high-fat-diet-fed mice","volume":"234","author":"Kurhe","year":"2017","journal-title":"Psychopharmacology"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1578326\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T05:28:26Z","timestamp":1750138106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1578326\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":59,"alternative-id":["10.3389\/fendo.2025.1578326"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1578326","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"article-number":"1578326"}}